RANBAXY

Introduction
Ranbaxy Laboratories Limited is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines. Ranbaxy is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The company is headquartered in India. It has presence in 49 countries, with manufacturing facilities in 11 and a diverse product portfolio. It’s a public ltd company. Ranbaxy
exports its products to 125 countries with ground operations in 46 and
manufacturing facilities in seven countries. The CEO of the company is Malvinder Mohan Singh.

Company Profile
Type: Public Ltd
Founded : 1961
Headquarters: Gurgaon, Haryana, India
Industry: Pharmaceutical
Websites: http://www.ranbaxy.com/

History
Ranbaxy was started by Ranjit Singh and Gurbax Singh in 1937 as a
distributor for a Japanese company Shionogi. Interestingly the name Ranbaxyis a portmanteau word from the names of its first owners Ranjit and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousins Ranjit Singh and Gurbax Singh. After Bhai Mohan Singh's son Parvinder Singh joined thecompany in 1967, the company saw a significant transformation in its business and scale. In 1998, Ranbaxy entered United States, the world’s largest pharmaceutical market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005. Ranbaxy is also one of the world's top 10 in that pharmaceutical category as well. Yet, with India's agreement to apply international patent law at the beginning of 2005, Ranbaxy has begun converting itself into a full-fledged research-based pharmaceutical company. A major part of this effort has been the establishment of the company's own research and development center, which has enabled the company to begin to
enter the new chemical entities (NCE) and novel drug delivery systems (NDDS) markets. In the mid-2000s, the company had a number of NCEs in progress, and had already launched its first NDDS product, a single daily dosage formulation of ciprofloxacin. Ranbaxy is a truly global operation, producing its pharmaceutical preparations in manufacturing facilities in sevencountries, supported by sales and marketing subsidiaries in 44 countries, reaching more than 100 countries throughout the world. The Company has
clocked sales of USD 286 Mn (2006) registering a growth of over 17%.Growing ahead of the market the Company has enhanced its competitive position in the domestic market through its focused approach. Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The robust R&D environment within the company for both drug discovery & &
development and for generics is designed to bring into sharper focus, theneeds of both equally.

• An introduction to Ranbaxy in India
  Ranbaxy is one of the leading pharmaceutical Companies in India commanding a market share of around 5%. The Company has clocked sales of USD 299 Mn(2008). Growing ahead of the market, the Company has enhanced its competitive position in the domestic market through its focused approach. The Company’s business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the Acute segment.
  Ranbaxy is a strong player in the Novel Drug Delivery System (NDDS) segment. Its product portfolio spans across Acute & Chronic Business covering Anti-infectives, Nutritionals, Gastro-intestinals, Pain Management (Acute) Cardiovasculars, Dermatologicals, Central Nervous Systems (Chronic) segments.
  Company’s India operations are a dominant force in a number of participating therapeutic segments, for example Anti-infectives, Statins, Dermatology and Pain Management. A publicly listed company, Ranbaxy India is also a member of IPA (Indian Pharmaceutical Alliance) & OPPI (Organization of Pharmaceutical Producers of India).
  • Company growing faster than the market.
  • One of the largest distribution networks that comprises 2500+ skilled field force. Dedicated task forces for specialised & chronic therapies
  • A strong player in the NDDS segment. Key brands include Cifran OD (Ciprofloxacin), Zanocin OD (Ofloxacin) & Sporidex AF (Cephalexin)
  • Strong brand building capabilities, reflected in the fact that around 20 brands feature in the “Top-300 brands of the Industry” list. Leading brands are Sporidex (Cephalexin), Cifran (Ciprofloxacin), Mox (Amoxycillin), Zanocin (Ofloxacin) & Volini (Diclofenac)
  • A well-built customer interface, with one of the highest customer coverage across India, and an excellent franchise with both Generalists & Specialists. This is proven by Ranbaxy India’s Corporate Image being perceived as ‘Best-in-Class’ by customers (source: AC Nielsen ORG MARG Report, June 2004)
  • Great emphasis is placed on Knowledge Management and Medico-marketing initiatives such as Advisory Board Meetings, Post Marketing Surveillance Studies and Continuous Medical Education programs. These have resulted in an excellent customer relationship with the medical fraternity. More than 2000 interface programs (Symposia, CME’s) are conducted and about 20 Clinical Papers published annually
  • With a futuristic approach, the India operations attempt to capitalize on the fast- emerging, high-growth segments with innovative products and services:
  Biological formulations such as Verorab (Rabies Vaccine) and Vaxigrip (Flu Vaccine), which require competencies to propagate the newer concepts in the market place. These products are being in-licensed or taken on Co-promotion from Sanofi Pastuer.
  High end anti-infectives such as Cilanem (Imipenem+Cilastatin) & Faronem (Faropenem) have been launched for the first time in India. Ranbaxy is championing the concept of Penems/ Carbapenmens , locally Dry Power & Metered Dose Inhalers have been launched in the Respiratory segment. All Metered Dose Inhalers are HFA based formulations, environment friendly inhalers. It is for the first time in India, that a company has launched its entire HFA propellant based MDI range. The world’s first novel product, Osovair (Formoterol + Ciclesonide) inhalation capsules has been introduced in the Indian market.
  Anti-diabetic franchise has been further consolidated with launch of Insucare (Insulin) with an innovative delivery mechanism - “Controlled Insulin Logistics” This ensures that the cold chain, vital for product efficacy, is maintained.
  A slew of products have been launched in the Dermatology segment: Suncross (Sunscreen lotion), Sotret (Isotretnoin), Eflora (Eflornithine)
  BOARD OF DIRECTORS
  Mr. Tejandra Khanna, Chairman
  Brian.W. Tempest, Vice Chairman
  Mr. Malvinder Mohan Singh, CEO & MD
  Mr. Atul Sobti, President
  Dr. P.S Joshi Director
  Ramesh L. Adige Executive Director
  
  PRODUCTS OFFERED
  · ANTI – INFECTION
  · G.I & NUTRITIONALS
  · CVS & DIABETES
  · CNS
  · NS AID & RELATED
  · ANTI ALLERGANTS
  · ANTI RETROVIRALS
  · UROLOGY
  · OTHERS
  SHARE IN MARKET